Trabectedin

Trabectedin
Clinical data
Pronunciation	/trəˈbɛktɪdɪn/; trə-BEK-ti-din
Trade names	Yondelis
Other names	ecteinascidin 743, ET-743
AHFS/Drugs.com	Monograph
MedlinePlus	a615059
License data	EU EMA: by INN; US DailyMed: Trabectedin;
Pregnancy; category	AU: D;
Routes of; administration	Intravenous
ATC code	L01CX01 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); UK: POM (Prescription only); US: ℞-only; EU: Rx-only; In general: ℞ (Prescription only);
Pharmacokinetic data
Bioavailability	Not applicable (IV only)
Protein binding	94 to 98%
Metabolism	Liver (mostly CYP3A4-mediated)
Elimination half-life	180 hours (mean)
Excretion	Mostly fecal
Identifiers
	IUPAC name (1'R,6R,6aR,7R,13S,14S,16R)-6',8,14-trihydroxy-7',9-dimethoxy-4,10,23-trimethyl-19-oxo-3',4',6,7,12,13,14,16-octahydrospiro[6,16-(epithiopropano-oxymethano)-7,13-imino-6aH-1,3-dioxolo[7,8]isoquino[3,2-b][3]benzazocine-20,1'(2'H)-isoquinolin]-5-yl acetate;
CAS Number	114899-77-3 ;
PubChem CID	108150;
IUPHAR/BPS	2774;
DrugBank	DB05109 ;
ChemSpider	97236 ;
UNII	ID0YZQ2TCP;
KEGG	D06199 ;
ChEBI	CHEBI:84050 ;
ChEMBL	ChEMBL297812 ;
CompTox Dashboard (EPA)	DTXSID2046880 ;
ECHA InfoCard	100.223.368
Chemical and physical data
Formula	C39H43N3O11S
Molar mass	761.84 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES Cc1cc2c(c(c1OC)O)[C@@H]3[C@@H]4[C@H]5c6c(c7c(c(c6OC(=O)C)C)OCO7)[C@@H](N4[C@H]([C@H](C2)N3C)O)COC(=O)[C@@]8(CS5)c9cc(c(cc9CCN8)O)OC;
	InChI InChI=1S/C39H43N3O11S/c1-16-9-20-10-22-37(46)42-23-13-50-38(47)39(21-12-25(48-5)24(44)11-19(21)7-8-40-39)14-54-36(30(42)29(41(22)4)26(20)31(45)32(16)49-6)28-27(23)35-34(51-15-52-35)17(2)33(28)53-18(3)43/h9,11-12,22-23,29-30,36-37,40,44-46H,7-8,10,13-15H2,1-6H3/t22-,23-,29+,30+,36+,37-,39+/m0/s1 ; Key:PKVRCIRHQMSYJX-AIFWHQITSA-N ;
	(what is this?) (verify)

Trabectedin, sold under the brand name Yondelis, is an antitumor chemotherapy medication for the treatment of advanced soft-tissue sarcoma and ovarian cancer.^[3]^[4]

The most common adverse reactions include nausea, fatigue, vomiting, constipation, decreased appetite, diarrhea, peripheral edema, dyspnea, and headache.^[3]^[4]

It is sold by Pharma Mar S.A. and Johnson and Johnson. It is approved for use in the European Union, Russia, South Korea and the United States. The European Commission and the U.S. Food and Drug Administration (FDA) granted orphan drug status to trabectedin for soft-tissue sarcomas and ovarian cancer.

^ ^a ^b "Yondelis". Therapeutic Goods Administration (TGA). 3 May 2021. Retrieved 6 September 2021.
^ "Yondelis 1 mg powder for concentrate for solution for infusion - Summary of Product Characteristics (SmPC)". (emc). 21 September 2020. Retrieved 30 September 2020.
^ ^a ^b ^c "Yondelis- trabectedin injection, powder, lyophilized, for solution". DailyMed. 22 September 2020. Retrieved 30 September 2020.
^ ^a ^b ^c "Yondelis EPAR". European Medicines Agency (EMA). 17 September 2018. Retrieved 30 September 2020.

[Yondelis_APM_summary-1] "Yondelis". Therapeutic Goods Administration (TGA). 3 May 2021. Retrieved 6 September 2021.

[2] "Yondelis 1 mg powder for concentrate for solution for infusion - Summary of Product Characteristics (SmPC)". (emc). 21 September 2020. Retrieved 30 September 2020.

[Yondelis_FDA_label-3] "Yondelis- trabectedin injection, powder, lyophilized, for solution". DailyMed. 22 September 2020. Retrieved 30 September 2020.

[Yondelis_EPAR-4] "Yondelis EPAR". European Medicines Agency (EMA). 17 September 2018. Retrieved 30 September 2020.

[1]

[2]

[3]

[4]